Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.

The article focuses on a randomised double-blind study which compared the efficacy of P2Y12 inhibitor ticagrelor with clopidogrel in patients with planned invasive strategy for coronary acute syndromes (PLATO). Several patients who were hospitalised for acute coronary syndromes were assigned randomly to ticagrelor and placebo and clopidogrel and placebo for 6-12 months. The study showed the occurrence of primary composite endpoint in fewer patients in the ticagrelor group compared with those in the clopidogrel. It also revealed that there was no difference between both groups in the rates of major bleeding or severe bleeding.